Sanford Barsky Profile Page
Professor of Pathology
Executive Director of the Cancer Center and Institute for Personalized Medicine
B.S. – University of Pittsburgh
M.D. – University of Pittsburgh School of Medicine
Sanford H. Barsky, MD, a native of McKees Rocks, a suburb of Pittsburgh, PA is an Alpha Omega Alpha (AOA) graduate of the University of Pittsburgh School of Medicine who completed his clinical training in Pathology and Laboratory Medicine at Harvard Medical School and Beth Israel Hospital, Boston, MA followed by research training at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD. Dr. Barsky was on the faculty of the University of California at Los Angeles (UCLA) for many years where he rose in academic rank from Assistant Professor to Full Professor with Tenure. Dr. Barsky then served as the Donald A. Senhauser Endowed Chairman of Pathology and Laboratory Medicine at The Ohio State University College of Medicine in Columbus, Ohio. Sanford then moved to Nevada in 2009 where he held joint appointments as Chairman of Pathology and Laboratory Medicine at the University of Nevada and Vice President of the Nevada Cancer Institute (NVCI) in Las Vegas. Dr. Barsky has previously served as member and Section Director of two NCI-designated Comprehensive Cancer Centers, the Jonsson and the James at UCLA and Ohio State respectively. Dr. Barsky is a Fellow of the American Association for the Advancement of Science and the recipient of numerous scientific honors and awards for his research on cancer invasion and metastasis, with a special emphasis on inflammatory breast cancer. Dr. Barsky has been awarded numerous peer-reviewed grants to support his research from national public and private funding agencies including the NCI, the American Cancer Society (ACS), the Department of Defense (DOD) and the Susan Komen Foundation. Dr. Barsky has published over 200 abstracts and 175 full-length papers and holds 15 US patents and several foreign patents. Dr. Barsky has been instrumental in the formation of two Silicon Valley Start-Ups, Pro Duct Health, Inc. and BioImagene, Inc., which created, respectively, novel medical device technology targeting the human breast and digital virtual pathology. Pro Duct Health, Inc. and BioImagene, Inc. were eventually acquired by two Fortune 500 companies, Hologic, Inc. and Roche-Ventana, Inc., respectively. Sanford feels honored to be afforded the opportunity to contribute his expertise in Cancer and in Personalized Medicine to the birth and development of the one of the newest allopathic medical schools and universities in California, the California University of Science and Medicine. Sanford, in his spare time, loves to play competitive Chess and Blackjack as well as cheer for his professional Pittsburgh sports teams.